Abonnement à la biblothèque: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publication de 6  numéros par an

ISSN Imprimer: 0743-4863

ISSN En ligne: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Pharmacogenomics and Its Potential Impact on Drug and Formulation Development

Volume 22, Numéro 5, 2005, pp. 465-492
DOI: 10.1615/CritRevTherDrugCarrierSyst.v22.i5.20
Get accessGet access

RÉSUMÉ

Recent advances in genomic research have provided the basis for new insights into the importance of genetic and genomic markers during the different stages of drug development. A new field of research, pharmacogenomics, which studies the relationship between drug effects and the genome, has emerged. Structural pharmacogenomics maps the complete DNA sequences of whole genomes (genotypes) including individual variations, and functional pharmacogenomics assesses the expression levels of thousands of genes in one single experiment. Together, these two areas of pharmacogenomics have generated massive databases, which have become a challenge for the research field of informatics and have fostered a new branch of research, bioinformatics. If skillfully used, the databases generated by pharmacogenomics together with data mining on the Web promise to improve the drug development process in a variety of areas: identification of drug targets, evaluation of toxicity, classification of diseases, evaluation of formulations, assessment of drug response and treatment, post-marketing applications, and development of personalized medicines.

CITÉ PAR
  1. Cunningham Mary Jane, Shah Mrinal, Toxicogenomics, in Pharmaceutical Sciences Encyclopedia, 2010. Crossref

  2. Jeong Sang-Hee, Cho Wan-Seob, Kim Ji-Eun, Cho Myung-Haing, Systems Toxicological Approach to the Risk Assessment of Nanomaterials, in General, Applied and Systems Toxicology, 2011. Crossref

  3. Realizing the Promise of Pharmacogenomics: Opportunities and Challenges, Biotechnology Law Report, 26, 3, 2007. Crossref

  4. Shlapobersky Mark, Wei Qun, Sullivan Sean, Vilalta Adrian, Vaxfectin®-adjuvanted seasonal influenza protein vaccine: Correlation of systemic and local immunological markers with formulation parameters, Vaccine, 27, 46, 2009. Crossref

  5. Castronuovo Cynthia Celeste, Cuestas María Luján, Oubiña José Raúl, Mathet Verónica Lidia, Effect of several PEO-PPO amphiphiles onbax,bcl-2, andhTERTmRNAs: An insight into apoptosis and cell immortalization induced in hepatoma cells by these polymeric excipients, Biotechnology and Applied Biochemistry, 63, 2, 2016. Crossref

  6. Vilalta Adrián, Shlapobersky Mark, Wei Qun, Planchon Rodrick, Rolland Alain, Sullivan Sean, Analysis of biomarkers after intramuscular injection of Vaxfectin®-formulated hCMV gB plasmid DNA, Vaccine, 27, 52, 2009. Crossref

  7. Gupta Sumeet, Jhawat Vikas, Quality by design (QbD) approach of pharmacogenomics in drug designing and formulation development for optimization of drug delivery systems, Journal of Controlled Release, 245, 2017. Crossref

  8. Allen Timothy Craig, Cagle Philip T., Bioinformatics and Omics, in Basic Concepts of Molecular Pathology, 2, 2009. Crossref

  9. Allen Timothy Craig, Cagle Philip T., Bioinformatics and Omics, in Molecular Pathology of Lung Diseases, 1, 2008. Crossref

  10. Cagle Philip T., Jagirdar Jaishree, Popper Helmut H., Molecular Genetics of Lung and Pleural Neoplasms, in Dail and Hammar’s Pulmonary Pathology, 2008. Crossref

  11. Nilsson Lennart J., Regnström Karin J., Pharmacogenomics in the Evaluation of Efficacy and Adverse Events During Clinical Development of Vaccines, in Pharmacogenomics in Drug Discovery and Development, 448, 2008. Crossref

  12. Jhawat Vikas, Gulia Monika, Gupta Sumeet, Maddiboyina Balaji, Dutt Rohit, Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy, Journal of Controlled Release, 327, 2020. Crossref

  13. Gagna Claude E, Lambert W Clark, Novel multistranded, alternative, plasmid and helical transitional DNA and RNA microarrays: implications for therapeutics, Pharmacogenomics, 10, 5, 2009. Crossref

  14. Ting S.L., Ip W.H., Tsang Albert H.C., Ho George T.S., An integrated electronic medical record system (iEMRS) with decision support capability in medical prescription, Journal of Systems and Information Technology, 14, 3, 2012. Crossref

Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections Prix et politiques d'abonnement Begell House Contactez-nous Language English 中文 Русский Português German French Spain